Moleculin Forms Scientific Advisory Board for Annamycin Development

HOUSTON, May 1, 2024 – Moleculin Biotech, Inc., a clinical-stage pharmaceutical firm known for its extensive portfolio of drug candidates aimed at tackling difficult tumors and viruses, has announced a significant development. The company has established an Annamycin Scientific Advisory Board and has appointed Dr. Martin Tallman, an internationally acclaimed clinician, as its first member.

Dr. Martin Tallman, widely recognized for his groundbreaking work in leukemia treatment, joins the board with a wealth of experience. His most recent role was at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, where he was instrumental in managing and developing new treatments for both acute and chronic leukemias. Dr. Tallman has also served as the chief of the Leukemia Service at Memorial Sloan Kettering Cancer Center and was a Professor of Medicine at Weill Cornell Medical College in New York. Notably, he was the president of the American Society of Hematology (ASH) in 2021 and has held prominent positions in several key oncology and hematology organizations.

Walter Klemp, Chairman and CEO of Moleculin, expressed optimism regarding the addition of Dr. Tallman to the advisory board. "The formation of this Scientific Advisory Board and the inclusion of Dr. Tallman's expertise significantly boost our Annamycin development programs. We remain committed to advancing our clinical and regulatory strategies as we embark on the next phase of development for Annamycin," Klemp stated.

Dr. Tallman shared his enthusiasm about joining the Moleculin team, highlighting the promising preliminary data for Annamycin in treating acute myeloid leukemia (AML). "The initial AML data for Annamycin suggest that it could become a groundbreaking treatment option. I am excited to collaborate with the Moleculin team to further its development and explore its potential in addressing significant unmet medical needs," he commented.

Annamycin has already garnered significant regulatory attention. It holds Fast Track Status and Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for treating relapsed or refractory AML. Additionally, it has received Orphan Drug Designation for treating soft tissue sarcoma (STS) lung metastases and from the European Medicines Agency for AML.

Moleculin Biotech continues to advance its pipeline of drug candidates. Besides Annamycin, which is a next-generation anthracycline designed to circumvent multidrug resistance mechanisms with minimal cardiotoxicity, the company is progressing with several other promising candidates. These include WP1066, an immune/transcription modulator targeting oncogenic transcription factors and stimulating immune responses against brain tumors, pancreatic cancer, and other cancers, and WP1220, an analog of WP1066 for treating cutaneous T-cell lymphoma. Furthermore, Moleculin is developing WP1122, an antimetabolite targeting viruses and various cancers, including brain and pancreatic tumors.

Moleculin remains dedicated to addressing critical medical challenges through innovative therapies. The company's expanding portfolio and the recent formation of the Annamycin Scientific Advisory Board underscore its commitment to advancing treatment options for hard-to-treat conditions.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!